Sorafenib-Induced Radiation in-Field Skin (SIRIS) Reaction: Unexpected Complication in Elder Hepatocellular Carcinoma Patients Received Sorafenib and Concurrent Radiation Therapy

We describe this phenomenon as Sorafenib induced radiation in-field skin (SIRIS) reaction, and the clinical course and radiation dosimetry of these patients were reviewed. The development of SIRIS reaction was primarily limited within the radiation treatment fields, and it occurred at a relatively low dose during the courses of RT. The SIRIS reaction progressed in a radiation dose-dependent manner and was recovered spontaneously after 3–4 weeks of radiation therapy. The SIRIS reaction implicates a unique phenomenon that systemic skin reaction of targeted therapeutics, such as sorafenib, might be limited or exacerbated in specific regions by local radiation therapy.
Source: International Journal of Gerontology - Category: Geriatrics Source Type: research